LCZ-Mont Tablet is a combination medication containing Levocetirizine 5mg and Montelukast 10mg, formulated for the management of allergic conditions. Levocetirizine is a second-generation antihistamine that selectively inhibits peripheral H1 receptors, effectively reducing symptoms such as sneezing, rhinorrhea, nasal itching, and urticaria by preventing the action of histamine. Montelukast is a leukotriene receptor antagonist that blocks cysteinyl leukotriene receptors, thereby diminishing inflammation, bronchoconstriction, and mucus production associated with allergic rhinitis and asthma. The synergistic action of these two agents provides comprehensive relief from both nasal and respiratory allergic symptoms. LCZ-Mont is indicated for the treatment of allergic rhinitis, chronic idiopathic urticaria, and as an adjunct therapy in asthma management to improve symptom control and reduce exacerbations. The combination offers the advantage of once-daily dosing, enhancing patient compliance. It is generally well tolerated; common adverse effects may include headache, fatigue, dry mouth, and gastrointestinal discomfort. Caution is advised in patients with hepatic or renal impairment, and it should be used under medical supervision. LCZ-Mont Tablet is a valuable therapeutic option for patients requiring dual-action treatment targeting histamine and leukotriene-mediated allergic responses.